logo-loader
viewCello Health PLC

Cello Health expects "strong" full-year outcome

Snapshot

  • Two divisions: Cello Health and Cello Signal
  • The group's dividend has risen every year for the past 13 years
  • Expansion in the US is key to future growth
  • Suitable acquisitions are being mulled to speed this aim
pills

Quick facts: Cello Health PLC

Price: 131.5 GBX

AIM:CLL
Market: AIM
Market Cap: £139.69 m
Follow

 

What it does

Cello Health PLC (LON:CLL) calls itself a healthcare-focused advisory group.

It has two arms: Health, which provides expertise, processes, intellectual property and market knowledge spanning the pharmaceutical, biotechnology, diagnostics, healthcare equipment and consumer health sectors.

And Signal, which provides “digital, social media and branding expertise” to companies, and is increasingly focused on health having previously been focused sectors such as technology and retail.

Cello’s big claim to fame is that it works with 24 of the top 25 pharmaceutical companies around the world.

 

How it is doing

In the six months to 30 June, Cello delivered net revenue of £54.5mln for the first six months of the year, which was up 6.8% on a year ago, with like-for-like constant currency net revenue up 4.5%.

Of the group’s two divisions, Health provided the bulk of growth, with revenue up 11.6% and like-for-likes of 8.2%, while Signal, which is historically second-half-weighted, was pretty much flat on a net revenue basis, with like-for-likes down 1%.

Underlying profit before tax and earnings per share for the first half were both up 12.7% to £5.7mln and 4.08p respectively, with PBT and EPS rising 40% on a statutory basis.

Keeping up its unbroken 13-year progressive dividend history, the interim payout was lifted 4.5% to 1.15p per share.

 

Inflexion points

In October, Cello sold social media analytics business Pulsar to Access Intelligence PLC (LON:ACC) in exchange for £4.5mln worth of shares.

The AIM-listed health advisory group said the sale would enable it to concentrate investment in the expanding healthcare section as well as Signal, its marketing services division.

Pulsar, which has gross assets of £3.2mln, will still work for Cello in cases of “mutual client opportunity”.

 

What the boss says: Mark Scott, chief executive

"The first half of 2019 has continued to see strong growth from Cello Health, notably in the US market. Cello Health Communications and Cello Health Consulting have made particularly pleasing progress."

"Good revenue visibility for the remainder of the year gives us confidence for a strong full-year outcome."

 

What analysts say

House broker finnCap said in a note dated September the healthcare outsourced advisory market, worth US$30bn, is "defensive and growing".

"In many respects the challenge is less about finding work but securing the staff to complete it. Consequently, management has over the past few years focused on hiring, training and retaining talent and the benefits are now coming through," analysts added.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Proactive's Ryan Long discusses the tin equivalent grade curve for tin deposits

Proactive's Ryan Long looks at the tin equivalent grade curve for the different types of tin deposit - defining high, mid and low-grade categories. He's calculated the tin equivalent grade using current metals prices where available for the bi product metals to show how the deposits sit...

6 days, 14 hours ago

RNS

Total Voting Rights

1 week, 6 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

on 14/11/19

Total Voting Rights

on 13/11/19

Total Voting Rights

on 7/10/19

Disposal

on 2/10/19

Interim Results

on 18/9/19

2 min read